Skip to content

Investigating the effect of binaural beats on brain electrical activity, interleukin-6 serum levels and depression severity in patients referred to the psychiatric clinic of Imam Khomeini Jiroft Hospital with major depressive disorder in 2024: A Randomized controlled trial study

Investigating the effect of binaural beats on brain electrical activity, interleukin-6 serum levels and depression severity in patients referred to the psychiatric clinic of Imam Khomeini Jiroft Hospital with major depressive disorder in 2024: A Randomized controlled trial study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20230709058730N1
Enrollment
96
Registered
2023-07-17
Start date
2023-08-23
Completion date
Unknown
Last updated
2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive Disorder. Major depressive disorder, single episode

Interventions

Intervention 1: Intervention group 1: patients with major depressive disorder who are treated with binaural beat delta wave with a frequency of 1 to 3 Hz. In addition to receiving their standard medic

Sponsors

Jeeroft University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 60 Years

Inclusion criteria

Inclusion criteria: All patients with major depressive disorder (MDD) who have not received any treatment so far. The age range of patients should be between 20 and 60 years. Patients must have healthy hearing function. Patients should not have been exposed to binaural beats stimulation.

Exclusion criteria

Exclusion criteria: Having or history of any neurological disease Alcohol consumption The presence of any underlying disease Pregnancy

Design outcomes

Primary

MeasureTime frame
Brain Electrical activity. Timepoint: The evaluation intervals of patients will be on day 0, day 14 and day 28. Method of measurement: Electroencephalography.;Interleukin 6 Serum level. Timepoint: The evaluation intervals of patients will be on day 0, day 14 and day 28. Method of measurement: ELISA laboratory kit.;Depression severity. Timepoint: The evaluation intervals of patients will be on day 0, day 14 and day 28. Method of measurement: Patient Health Questionnaire (PHQ-9).

Secondary

MeasureTime frame
Quality of Life. Timepoint: The evaluation intervals of patients will be on day 0, day 14 and day 28. Method of measurement: The World Health Organization Quality of Life – BREF (WHOQOL-BREF).;Sleep quality. Timepoint: The evaluation intervals of patients will be on day 0, day 14 and day 28. Method of measurement: Pittsburgh Sleep Quality Index (PSQI).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Pourfridoni

Jeeroft University of Medical Sciences

Pourfridoni.m@gmail.com+98 34 4331 7802

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026